Uchaipichat Verawan, Galetin Aleksandra, Houston J Brian, Mackenzie Peter I, Williams J Andrew, Miners John O
Department of Clinical Pharmacology, Flinders University, Flinders Medical Centre, Adelaide, Australia.
Mol Pharmacol. 2008 Oct;74(4):1152-62. doi: 10.1124/mol.108.048645. Epub 2008 Jul 22.
Interactions between the UGT2B7-catalyzed glucuronidation of zidovudine (AZT), 4-methylumbelliferone (4MU), and 1-naphthol (1NP) were analyzed using multisite and empirical kinetic models to explore the existence of multiple substrate and effector binding sites within this important drug metabolizing enzyme. 4MU and 1NP glucuronidation by UGT2B7 exhibit sigmoidal kinetics characteristic of homotropic cooperativity (autoactivation), which may be modeled assuming the existence of two equivalent, interacting substrate binding sites. In contrast, UGT2B7-catalyzed AZT glucuronidation follows hyperbolic (Michaelis-Menten) kinetics. Although 4MU and 1NP decreased the binding affinity of AZT, the kinetics of AZT glucuronidation changed from hyperbolic to sigmoidal in the presence of both modifiers. Data were well described by a generic two-substrate binding site model in which there is no interaction between the sites in the absence of 4MU or 1NP, but heterotropic cooperativity results from the binding of modifier. Inhibition of 4MU and 1NP glucuronidation by AZT and interactions between 4MU and 1NP required more complex three-site models, where the modifier acts via a distinct effector site to alter either substrate binding affinity or Vmax without affecting the homotropic cooperativity characteristic of 4MU and 1NP glucuronidation. It is noteworthy that 1NP inhibited 4MU glucuronidation, whereas 4MU activated 1NP glucuronidation. The results are consistent with the existence of two "catalytic" sites for each substrate within the UGT2B7 active site, along with multiple effector sites. The multiplicity of binding and effector sites results in complex kinetic interactions between UGT2B7 substrates, which potentially complicates inhibition screening studies.
使用多位点和经验动力学模型分析了齐多夫定(AZT)、4-甲基伞形酮(4MU)和1-萘酚(1NP)在UGT2B7催化下的葡萄糖醛酸化相互作用,以探究这种重要的药物代谢酶中多个底物和效应物结合位点的存在情况。UGT2B7催化的4MU和1NP葡萄糖醛酸化呈现同促协同作用(自激活)的S形动力学特征,这可以通过假设存在两个等效的、相互作用的底物结合位点来建模。相比之下,UGT2B7催化的AZT葡萄糖醛酸化遵循双曲线(米氏)动力学。虽然4MU和1NP降低了AZT的结合亲和力,但在两种调节剂存在的情况下,AZT葡萄糖醛酸化的动力学从双曲线变为S形。通用的双底物结合位点模型能很好地描述这些数据,在该模型中,在不存在4MU或1NP时位点之间没有相互作用,但调节剂的结合会导致异促协同作用。AZT对4MU和1NP葡萄糖醛酸化的抑制以及4MU和1NP之间的相互作用需要更复杂的三位点模型,其中调节剂通过一个独特的效应物位点起作用,以改变底物结合亲和力或Vmax,而不影响4MU和1NP葡萄糖醛酸化的同促协同作用特征。值得注意的是,1NP抑制4MU葡萄糖醛酸化,而4MU激活1NP葡萄糖醛酸化。结果与UGT2B7活性位点内每个底物存在两个“催化”位点以及多个效应物位点一致。结合位点和效应物位点的多样性导致UGT2B7底物之间存在复杂的动力学相互作用,这可能会使抑制筛选研究变得复杂。